Tirzepatide Matches Competitor’s Cardioprotective Benefits for Diabetics

By News Health
44 minutes Ago

(MedPage Today) — The dual GIP/GLP-1 receptor agonist tirzepatide (Mounjaro, Zepbound) was just as cardioprotective as the GLP-1 drug dulaglutide (Trulicity) in patients with type 2 diabetes and atherosclerotic cardiovascular disease, a large…

Source link : https://www.medpagetoday.com/cardiology/prevention/119074

Author :

Publish date : 2025-12-17 22:47:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

Two Extended-Release Buprenorphine Doses Effective in High-Risk Opioid Use Disorder

Major Developments in Psoriatic Disease

ADHD App Cleared; Anti-Inflammatories for Depression; Charges Over Adderall Scripts

Big Bump in Concierge, Direct Primary Care in Recent Years

Undesired Weight Gain Common in HIV Patients on ART

Improving Oral Chemotherapy Adherence in Pediatric ALL